Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
epilepsy
Biotech
SK's $795M deal to usher Biohaven’s epilepsy therapy towards FDA
SK has strengthened its epilepsy offering by paying $350 million upfront to help speed Biohaven’s Kv7 ion channel activator on its way to market.
James Waldron
Aug 26, 2026 4:47am
Jazz pays $820M to add epilepsy-focused Actio to its orchestra
Aug 10, 2026 10:40am
Praxis faces FDA delay, analysts point finger at agency layoffs
Jun 30, 2026 4:13am
Praxis pauses one of its seizure programs after phase 2 fail
Jun 2, 2026 5:23am
Xenon epilepsy candidate 'blows away' ph. 3 expectations
Mar 9, 2026 10:55am
Biohaven reduces scope of R&D cuts as pipeline progresses
Mar 3, 2026 9:00am
